Literature DB >> 18422871

Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.

G Li1, S H Basagoudanavar, D C Gowda.   

Abstract

The glycosylphosphatidylinositol (GPI)-anchored Plasmodium falciparum merozoite surface protein 1 (MSP-1) is a widely studied malaria vaccine candidate. The C-terminal 19-kDa portion of MSP-1 (MSP-1(19)) is of particular interest because this polypeptide moiety remains bound to the parasite even after erythrocyte invasion, while the remainder of MSP-1 is shed during invasion. Studies have shown that antibodies against MSP-1(19) inhibit merozoite invasion of erythrocytes efficiently, and that MSP-1(19) produces protective immunity in mice and monkeys. To investigate the efficacy of MSP-1(19 )DNA vaccine and role of GPI anchor moiety in the immunogenicity of MSP-1(19), we constructed expression vectors that produce MSP-1(19) as either secretory or GPI-anchored polypeptide. Both constructs efficiently expressed MSP-1(19) in transfected HEK-293 cells. While the recombinant plasmid lacking GPI anchor signal sequence expressed MSP-1(19) mainly as secreted polypeptide, that containing GPI anchor signal sequence produced GPI-anchored MSP-1(19 )on cell surface. In immunized mice, both constructs produced substantial levels of MSP-1(19)-specific IgG1, IgG2a, IgG2b, IgG3, IgA and IgM antibodies. In both cases, the IgG1 level was significantly higher than other isotypes. Interestingly, the plasmid containing GPI anchor signal sequence produced significantly higher levels of IgG2a and IgG2b than the plasmid that lacks GPI signal sequence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422871      PMCID: PMC2701305          DOI: 10.1111/j.1365-3024.2008.01027.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  26 in total

1.  Influence of glycosylphosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5.

Authors:  Lina Wang; Lukasz Kedzierski; Louis Schofield; Ross L Coppel
Journal:  Vaccine       Date:  2005-04-14       Impact factor: 3.641

Review 2.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; M A Liu
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

3.  Glycosylation and proteolytic processing of 70 kDa C-terminal recombinant polypeptides of Plasmodium falciparum merozoite surface protein 1 expressed in mammalian cells.

Authors:  S Yang; D Nikodem; E A Davidson; D C Gowda
Journal:  Glycobiology       Date:  1999-12       Impact factor: 4.313

4.  Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.

Authors:  Ute Woehlbier; Christian Epp; Christian W Kauth; Rolf Lutz; Carole A Long; Boubacar Coulibaly; Bocar Kouyaté; Myriam Arevalo-Herrera; Sócrates Herrera; Hermann Bujard
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

Authors:  Christian F Ockenhouse; Evelina Angov; Kent E Kester; Carter Diggs; Lorraine Soisson; James F Cummings; Ann V Stewart; Dupeh R Palmer; Babita Mahajan; Urszula Krzych; Nadia Tornieporth; M Delchambre; M Vanhandenhove; Opokua Ofori-Anyinam; Joe Cohen; Jeffrey A Lyon; D Gray Heppner
Journal:  Vaccine       Date:  2005-11-28       Impact factor: 3.641

6.  The global distribution of clinical episodes of Plasmodium falciparum malaria.

Authors:  Robert W Snow; Carlos A Guerra; Abdisalan M Noor; Hla Y Myint; Simon I Hay
Journal:  Nature       Date:  2005-03-10       Impact factor: 49.962

7.  Plasmodium falciparum GPI mannosyltransferase-III has novel signature sequence and is functional.

Authors:  Suresh H Basagoudanavar; Xiaorong Feng; Gowdahalli Krishnegowda; Arivalagan Muthusamy; D Channe Gowda
Journal:  Biochem Biophys Res Commun       Date:  2007-10-22       Impact factor: 3.575

8.  Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

Authors:  D C Kaslow; G Hui; S Kumar
Journal:  Mol Biochem Parasitol       Date:  1994-02       Impact factor: 1.759

9.  Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal.

Authors:  M C Field; P Moran; W Li; G A Keller; I W Caras
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

10.  Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.

Authors:  A F Egan; P Burghaus; P Druilhe; A A Holder; E M Riley
Journal:  Parasite Immunol       Date:  1999-03       Impact factor: 2.280

View more
  4 in total

1.  In vitro antiplasmodial activity of cepharanthine.

Authors:  Camille Desgrouas; Charles Chapus; Jérôme Desplans; Christelle Travaille; Aurélie Pascual; Béatrice Baghdikian; Evelyne Ollivier; Daniel Parzy; Nicolas Taudon
Journal:  Malar J       Date:  2014-08-22       Impact factor: 2.979

2.  A novel Pfs38 protein complex on the surface of Plasmodium falciparum blood-stage merozoites.

Authors:  Gourab Paul; Arunaditya Deshmukh; Inderjeet Kaur; Sumit Rathore; Surbhi Dabral; Ashutosh Panda; Susheel Kumar Singh; Asif Mohmmed; Michael Theisen; Pawan Malhotra
Journal:  Malar J       Date:  2017-02-16       Impact factor: 2.979

3.  Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.

Authors:  Neeraj Kapoor; Ivana Vanjak; James Rozzelle; Aym Berges; Wei Chan; Gang Yin; Cuong Tran; Aaron K Sato; Alexander R Steiner; Thao P Pham; Ashley J Birkett; Carole A Long; Jeff Fairman; Kazutoyo Miura
Journal:  Biochemistry       Date:  2018-01-16       Impact factor: 3.162

4.  An Erythrocyte Membrane-Associated Antigen, PvTRAg-26 of Plasmodium vivax: A Study of Its Antigenicity and Immunogenicity.

Authors:  Liping Fan; Jinxing Xia; Jilong Shen; Qiang Fang; Hui Xia; Meijuan Zheng; Jin-Hee Han; Eun-Taek Han; Bo Wang; Yuanhong Xu
Journal:  Front Public Health       Date:  2020-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.